Clinical Trial Update: 68Ga-RM2 for PET/CT of Gastrin Releasing Peptide Receptor (GRPr) Expression in Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating 68Ga-RM2 PET/CT imaging of GRPr expression in prostate cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 68Ga-RM2

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-05-18